Pentetreotide
Alternative Names: MP 1727; OctreoScan; SomatoTherLatest Information Update: 25 Sep 2021
At a glance
- Originator Novartis
- Developer Bristol-Myers Squibb; Louisiana State University; Novartis
- Class Cyclic peptides; Radiopharmaceutical diagnostics; Somatostatins
- Mechanism of Action Single-photon emission-computed tomography enhancers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Neuroendocrine tumours
Most Recent Events
- 10 Dec 2001 Launched for Neuroendocrine tumour diagnosis in Canada (IV)
- 01 Nov 2000 Mallinckrodt has been acquired by Tyco International
- 29 May 2000 DuPont Pharmaceuticals has exclusive distribution rights in Canada for pentetreotide